Skip to main content
S&P 5007,704.81+1.80%DOW53,258.14+2.84%NASDAQ25,884.14+2.02%BTC$80,535.00+3.76%ETH$2,432.59+6.02%GOLD$4,078.30+3.50%OIL$88.78-7.61%
Smart Investors Daily
SID Premium
BioStem Technologies, Inc. logo

OTC · BSEM

BioStem Technologies, Inc.

Healthcare · Biotechnology

$1.15

Up+$0.02 (+1.74%)

Updated Nov 4, 2026, 5:49 PM

SID Score

2.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
70.33M
P/E ratio
3.5
Dividend yield
0.00%
52-week range
$1.11 – $5.44
Volume
297.31K
Avg. volume
68.56K

Price performance · BSEM

BSEM price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

BSEM closed at $1.15 after 21 trading sessions, down 53.44% for the selected period.

Last close
$1.15
Period change
-53.44%
Period low
$1.12
Period high
$2.64
Daily close
View OHLC price history
BSEM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.21$1.27$1.04$1.15297.31K
Nov 2, 2026$1.20$1.29$1.14$1.16193.99K
Oct 30, 2026$1.29$1.29$1.11$1.12145.6K
Oct 29, 2026$1.54$1.59$1.2103$1.29263.73K
Oct 28, 2026$1.6055$1.62$1.45$1.51329.07K
Oct 27, 2026$1.59$1.5999$1.42$1.48185.9K
Oct 26, 2026$1.57$1.61$1.40$1.54169.46K
Oct 23, 2026$1.68$1.74$1.57$1.57134.01K
Oct 22, 2026$1.64$1.70$1.60$1.6649.64K
Oct 21, 2026$1.62$1.78$1.55$1.68197.23K
Oct 20, 2026$1.58$1.75$1.57$1.64163.39K
Oct 19, 2026$2.10$2.10$1.45$1.54404.41K
Oct 16, 2026$2.03$2.10$2.03$2.0933.41K
Oct 15, 2026$2.15$2.30$1.8801$2.04102.37K
Oct 14, 2026$2.16$2.2989$2.10$2.1170.02K
Oct 13, 2026$2.49$2.49$2.1315$2.25113.05K
Oct 12, 2026$2.46$2.495$2.37$2.4436.8K
Oct 9, 2026$2.60$2.6999$2.46$2.4766.22K
Oct 8, 2026$2.40$2.77$2.36$2.64258.02K
Oct 7, 2026$2.50$2.69$2.36$2.3987.34K
Oct 6, 2026$2.76$2.79$2.45$2.47128.62K

Latest BSEM news

The latest Smart Investors Daily articles mentioning BSEM.

Stock researchCompany · Overview

BSEM research

Overview

Company profile and research snapshot.

Company profile

BIOSTEM TECHNOLOGIES NEW

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BSEM recent ratings
DateFirmRatingTarget
Nov 7, 2022Zacks Investment ResearchBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026

Conference call and webcast to be held at 4:30 PM ETPOMPANO BEACH, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its third quarter 2026 financial results on Thursday, November 12, 2026, and will host a conference call and webcast at 4:30 PM ET. The webcast

Yahoo · Oct 8, 2026

BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options

Leadership investment supports expanded hospital commercial pushPOMPANO BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced its Chair and Chief Executive Officer, Jason Matuszewski, and Chief Operating Officer, Andrew Van Vurst, each exercised a portion of their outstandi

Yahoo · Oct 1, 2026

BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio

Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company's sterile placental allograft, micronized wound care, and umbilical cord extract technologiesPOMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the Unite

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By